2004
November 5, 2004
Panacea Pharmaceuticals, Inc. Presents New Findings on its Neuroprotection and
Parkinson’s Disease Programs at the Annual Meeting of the Society for Neuroscience
September 21, 2004
Panacea Pharmaceuticals, Inc. Announces Evidence that HAAH Oncology Target Regulates Metastatic Tumor Cell Growth and that Levels Correlate with Poor Prognosis
September 14, 2004
Panacea Pharmaceuticals, Inc. Awarded SBIR from National Institute of Aging for Alzheimer's Disease Program
September 10, 2004
Panacea Pharmaceuticals, Inc. Announces Management Change and Promotions
July 20, 2004
Panacea Pharmaceuticals, Inc. Presents New Findings on PAN-811 at 9th International Conference on Alzheimer’s Disease and Related Disorders
May 3, 2004
Panacea Pharmaceuticals, Inc. Announces Collaboration with M.D. Anderson Cancer Center for HAAH Oncology Program
April 30, 2004
Panacea Pharmaceuticals, Inc. Reacquires Rights to HAAH Oncology Program from MedImmune, Inc.
April 6, 2004
Panacea Pharmaceuticals, Inc. Awarded SBIR from National Institute of Neurological Disorders and Stroke to Develop Neuroprotectants for Stroke and Other Ischemia-Related Conditions
March 17, 2004
Panacea Pharmaceuticals, Inc. Announces Collaboration with Walter Reed Army Institute of Research for Pre-Clinical Studies on Drug Candidates for Stroke and Other Neurodegenerative Conditions
